APA

Huizinga T. W. J., Batalov A., Stoilov R., Lloyd E., Wagner T., Saurigny D., Souberbielle B. & Esfandiari E. (20171121). Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. : Arthritis research & therapy.

Chicago

Huizinga T W J, Batalov A, Stoilov R, Lloyd E, Wagner T, Saurigny D, Souberbielle B and Esfandiari E. 20171121. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. : Arthritis research & therapy.

Harvard

Huizinga T. W. J., Batalov A., Stoilov R., Lloyd E., Wagner T., Saurigny D., Souberbielle B. and Esfandiari E. (20171121). Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. : Arthritis research & therapy.

MLA

Huizinga T W J, Batalov A, Stoilov R, Lloyd E, Wagner T, Saurigny D, Souberbielle B and Esfandiari E. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. : Arthritis research & therapy. 20171121.